North America Continuous Glucose Monitoring Market - Strategic Insights and Forecasts (2026-2031)

The North American Continuous Glucose Monitoring (CGM) market is forecast to grow at a CAGR of 18.8%, reaching USD 18.0 billion in 2031 from USD 7.6 billion in 2026.

Key Highlights

Market Overview

Commercial demand is increasingly supported by reimbursement expansion, higher physician confidence in CGM-guided therapy, and growing use among both insulin-treated and selected non-insulin-treated diabetes patients. According to the U.S. Centers for Disease Control and Prevention (CDC), CGMs enable continuous glucose measurement, provide trend alerts, and are now recommended for a broad range of diabetes patients because they improve daily glucose management and increase time spent within target glucose ranges.

Purchasing decisions increasingly extend beyond sensor accuracy. Healthcare providers evaluate interoperability with insulin pumps, electronic health records, mobile applications, remote patient monitoring platforms, data-sharing capabilities, reimbursement eligibility, and patient training requirements before selecting a device. These considerations have encouraged manufacturers to position CGMs as integrated disease-management platforms rather than standalone monitoring products.

Commercial activity remains concentrated around a limited number of established manufacturers with regulatory approvals, manufacturing capabilities, clinical evidence, and extensive reimbursement experience. Product differentiation increasingly depends on longer sensor wear, simplified insertion, lower calibration requirements, predictive glucose alerts, and software-enabled clinical decision support. Official FDA clearances continue to broaden product availability across prescription and over-the-counter categories, while manufacturers continue expanding indications for wider patient populations.

Value creation across the market increasingly depends on recurring sensor replacement rather than one-time hardware sales. Recurring consumable demand, digital health integration, clinician engagement, reimbursement support, and post-sale services collectively shape supplier revenue, while healthcare systems evaluate CGMs based on their ability to reduce acute complications, improve long-term diabetes management, and support value-based care models.

Key Market Indicators

Key indicator: More than 38 million Americans live with diabetes, according to the CDC.
Commercial meaning: This sustained patient base supports recurring demand for disposable sensors, digital monitoring services, and integrated diabetes management solutions.

Market Drivers

Expansion of reimbursement eligibility across diabetes care. Insurance coverage has become one of the strongest commercial drivers because CGM adoption remains closely linked to affordability. Medicare, Medicaid programs, and private insurers increasingly reimburse eligible patients using insulin therapy and selected high-risk diabetes populations, reducing financial barriers to long-term use. The CDC notes that many insured patients now receive CGM coverage with relatively limited monthly costs, encouraging physicians to recommend continuous monitoring earlier in disease management. Suppliers continue investing in reimbursement support teams, physician education, and payer engagement because broader coverage directly increases recurring sensor utilization.

Clinical preference for continuous glucose data instead of episodic measurements. Diabetes care has shifted toward continuous assessment of glucose variability rather than isolated blood glucose readings. Healthcare providers increasingly use metrics such as Time in Range, glucose variability, and hypoglycemia alerts to personalize treatment decisions. These capabilities improve therapeutic adjustments for insulin users while enabling remote patient monitoring between clinic visits. Manufacturers have expanded software analytics, cloud connectivity, and physician dashboards to meet these clinical requirements, making digital ecosystem capabilities an increasingly important purchasing criterion alongside sensor accuracy.

Broader product availability through regulatory approvals and device innovation. Continuous product development has increased commercial opportunities beyond traditional insulin-dependent diabetes management. FDA clearances have expanded available CGM options through longer sensor wear periods, over-the-counter products, and new integrated monitoring systems. Recent FDA authorizations include additional Dexcom G7 configurations, Abbott FreeStyle Libre platform updates, and Senseonics' sensor technologies, allowing suppliers to address different patient needs while strengthening competitive differentiation through convenience, interoperability, and reduced maintenance requirements. These approvals also encourage healthcare providers to adopt newer platforms with improved usability and clinical workflow compatibility.

Growing integration with automated insulin delivery systems. Diabetes management increasingly depends on coordinated device ecosystems rather than individual products. CGMs now function as core inputs for automated insulin delivery systems, insulin pumps, and digital therapeutic platforms. This integration improves dosing precision while reducing manual intervention for patients requiring intensive glucose management. Companies including Dexcom, Medtronic, Tandem Diabetes Care, and Insulet continue expanding interoperability through software partnerships and connected device ecosystems because integrated solutions create higher switching costs and generate recurring revenue from both sensors and associated diabetes management technologies.

Market Restraints and Challenges

Manufacturing quality requirements and regulatory compliance costs. Continuous glucose monitoring devices operate within highly regulated medical device frameworks requiring extensive quality management, manufacturing validation, post-market surveillance, and corrective action processes. FDA inspections demonstrate that compliance remains an ongoing operational requirement even for established manufacturers. Manufacturing observations or warning letters may require additional investment in quality systems, delay product expansion, and increase regulatory oversight, affecting production planning and operating costs. Smaller manufacturers face greater challenges because compliance expenses represent a larger proportion of total operating expenditure.

Uneven reimbursement across patient populations. Although reimbursement has expanded considerably, coverage remains inconsistent across insurers, provinces, states, and patient categories. Patients receiving intensive insulin therapy generally experience broader reimbursement than individuals managing diabetes through lifestyle modification or oral medication. Coverage restrictions influence prescribing behavior and may delay adoption despite clinical evidence supporting broader CGM use. Manufacturers increasingly pursue additional clinical studies and health-economic evidence to demonstrate cost effectiveness for wider reimbursement eligibility and improved payer acceptance.

Recurring sensor replacement increases long-term treatment costs. The commercial model for CGMs depends on regular sensor replacement throughout the year. While this generates recurring supplier revenue, it also increases lifetime treatment costs for patients lacking comprehensive insurance coverage. Disposable sensor consumption, transmitter replacement, mobile connectivity requirements, and software ecosystem costs collectively influence purchasing decisions. Healthcare providers therefore consider reimbursement status alongside clinical performance when recommending specific CGM platforms, particularly for patients with long-term chronic disease management needs.

Interoperability and technology transition challenges. Hospitals and diabetes clinics increasingly prefer monitoring platforms that connect seamlessly with insulin pumps, electronic health records, remote monitoring systems, and digital health applications. Legacy systems with limited compatibility may require software upgrades, clinician retraining, or replacement investments before full integration becomes possible. Manufacturers continue expanding interoperability because purchasing decisions increasingly depend on ecosystem compatibility rather than sensor performance alone. This raises development costs while intensifying competition among suppliers seeking preferred positions within integrated diabetes management platforms.

Major Segment Analysis

Diabetes Patients

Diabetes patients represent the commercially most important application segment because continuous glucose monitoring is increasingly incorporated into routine disease management for individuals requiring intensive insulin therapy as well as selected patients with Type 2 diabetes. Clinical guidelines, broader reimbursement, and physician acceptance have shifted CGMs from specialist endocrinology practices toward wider outpatient care. Purchasing decisions emphasize measurement accuracy, alarm reliability, sensor wear duration, mobile connectivity, ease of insertion, and compatibility with automated insulin delivery systems rather than device price alone.

Manufacturers increasingly compete by expanding approved patient indications and improving ecosystem interoperability. Recent FDA clearances for the Dexcom G7 15-Day CGM System, Abbott's FreeStyle Libre platform, and Senseonics' Eversense 365 demonstrate continued investment in extending wear duration and improving patient convenience. Demand is further supported by recurring sensor replacement, creating predictable revenue streams while encouraging suppliers to strengthen patient support services, digital coaching, and physician engagement. Despite this momentum, adoption among non-intensive insulin users remains influenced by reimbursement eligibility and long-term affordability, making payer coverage a decisive factor for sustained expansion.

Regional Analysis

The United States accounts for the largest commercial opportunity within North America because it combines a large diabetes population with extensive specialist care infrastructure, favorable reimbursement mechanisms, and rapid regulatory approvals for new CGM technologies. FDA clearances continue to expand available products across prescription and integrated monitoring categories, while Medicare and commercial insurers have broadened eligibility for many insulin-treated patients. Competition therefore focuses on technology differentiation, clinical evidence, digital integration, and service capability rather than basic device availability.

Canada presents stable demand supported by universal healthcare systems and provincial reimbursement programs, although coverage criteria differ across provinces. Public reimbursement has improved access for eligible diabetes patients, encouraging physicians to recommend CGMs earlier in disease management. Commercial success depends on demonstrating health-economic value to provincial payers while maintaining distributor networks that support long-term patient management.

Mexico represents an expanding opportunity because diabetes remains a major public health challenge, yet CGM penetration remains comparatively lower than in the United States and Canada. Demand is concentrated among private hospitals, diabetes specialists, and higher-income urban populations where patients are more likely to purchase advanced monitoring systems. Affordability, insurance coverage, and healthcare infrastructure continue to influence adoption rates more strongly than technology availability.

Across the remaining North American market, manufacturers increasingly rely on regional distributors, physician education, and digital health partnerships to expand adoption. Companies are also localizing commercial support, improving multilingual digital applications, and strengthening post-sales services to improve patient adherence and clinician confidence.

Competitive Landscape

The North American CGM market remains moderately concentrated, with Dexcom Inc., Abbott Laboratories, and Medtronic plc accounting for much of the established commercial presence through extensive regulatory approvals, manufacturing capacity, and clinical validation. Senseonics Holdings Inc. differentiates its portfolio through long-duration implantable sensors, while Tandem Diabetes Care Inc. and Insulet Corporation strengthen their market position through integration of CGMs with automated insulin delivery platforms. A recent SEC filing also highlights collaboration between insulin delivery developers and Abbott to expand integrated diabetes management systems, reflecting increasing emphasis on interoperability rather than standalone devices.

Companies increasingly compete through software ecosystems, cloud connectivity, reimbursement support, physician training, and recurring sensor supply rather than hardware specifications alone. Manufacturing quality has also become a competitive differentiator because regulatory compliance directly influences customer confidence and product availability. Recent FDA actions affecting selected sensor products demonstrate that sustained investment in quality management systems remains essential for maintaining commercial performance and protecting long-term market share.

Recent Developments

• December 2025: Medtronic commercially launched the MiniMed 780G system integrated with Abbott's Instinct CGM sensor across the United States. The launch expands automated insulin delivery options, combining Medtronic's pump technology with Abbott's next-generation CGM platform for diabetes management.

• September 2025: Senseonics signed an agreement to assume commercialization and distribution of its Eversense 365 CGM from Ascensia Diabetes Care. The strategic transaction gives Senseonics direct control of U.S. sales, marketing, and future commercial expansion beginning in 2026.

• September 2025: Medtronic received U.S. FDA clearance for MiniMed 780G integration with Abbott's Instinct CGM sensor, including expanded indications for people with Type 2 diabetes. The approval strengthened Medtronic's North American automated insulin delivery portfolio.

• April 2025: Sequel Med Tech and Senseonics announced a commercial development agreement integrating the twiist automated insulin delivery system with the Eversense 365 implantable CGM. The collaboration created the first AID platform compatible with a one-year continuous glucose monitor.

• April 2025: The U.S. FDA granted clearance for the Dexcom G7 15-Day Continuous Glucose Monitoring System. The approval extends sensor wear duration and strengthens competition around patient convenience and recurring sensor replacement.

Regulatory and Policy Environment

Regulation remains one of the defining commercial influences in the North American CGM market because product approval, reimbursement, manufacturing quality, cybersecurity, and post-market surveillance collectively determine market access. In the United States, the FDA regulates integrated continuous glucose monitoring systems through established medical device pathways, requiring manufacturers to demonstrate safety, performance, manufacturing consistency, and substantial equivalence where applicable. Continued approvals for Dexcom, Abbott, and Senseonics illustrate active regulatory support for incremental product improvements while maintaining rigorous quality oversight.

Reimbursement policies remain equally important. Medicare coverage expansion has improved patient access for eligible diabetes populations, while private insurers increasingly align coverage with evidence-based clinical guidelines. Canada follows a provincial reimbursement model, creating regional differences in patient eligibility and procurement practices. Mexico continues expanding diabetes care initiatives, although reimbursement remains more limited than in the United States and Canada.

Manufacturers must also comply with post-market reporting requirements, corrective action procedures, and quality management regulations throughout the product lifecycle. Recent FDA safety actions affecting selected CGM sensors demonstrate that regulatory oversight extends well beyond product approval and directly influences commercial operations, supply continuity, and customer confidence.

Outlook and Strategic Implications

Demand during the 2026-2031 forecast period is expected to be shaped less by first-time technology adoption and more by broader reimbursement, replacement demand, ecosystem integration, and expansion into additional diabetes populations. Competition will increasingly depend on software capability, interoperability, manufacturing quality, clinical evidence, and payer engagement rather than incremental hardware improvements alone.

Strategic priorities across the value chain include:

• Manufacturers: Expand approved indications, strengthen manufacturing quality systems, and improve interoperability with automated insulin delivery platforms.

• Healthcare providers: Prioritize CGMs that integrate efficiently with clinical workflows, electronic health records, and remote patient monitoring programs.

• Payers: Continue evaluating reimbursement using clinical outcomes, reduced hospitalization risk, and long-term diabetes management costs.

• Technology partners: Develop secure digital platforms supporting data sharing, predictive analytics, and connected diabetes care.

• Investors: Focus on companies demonstrating recurring sensor revenue, regulatory execution, diversified manufacturing, and integrated diabetes ecosystems.

The market is expected to remain innovation-driven throughout the forecast period, although commercial success will increasingly depend on sustained regulatory compliance, reimbursement expansion, manufacturing resilience, and the ability to deliver connected diabetes management solutions that improve long-term clinical outcomes while reducing overall healthcare costs.

North America Continuous Glucose Monitoring Market Scope: